Neurodawn Pharmaceutical Co., Ltd.

This early-stage study tested a new drug, Y-3, in 20 healthy adults to see if it is safe and how the body processes it. Participants received a single dose of either 40 mg, 60 mg, or a placebo. The goal was to gather basic safety and drug-level information, not to treat any disea…

This completed Phase 1 trial in 24 healthy Chinese adults aimed to see if a new drug called Y-3 (given as an injection) changes how the body processes three common medications: repaglinide (for diabetes), warfarin (a blood thinner), and omeprazole (for heartburn). Participants to…